Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors

Alpelisib is a selective inhibitor of PI3Kα, shown to improve outcomes for PIK3CA mutant, hormone receptor positive (HR+) metastatic breast cancers (MBC) when combined with antiestrogen therapy. To uncover mechanisms of resistance, we conducted a detailed, longitudinal analysis of tumor and plasma c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nat Cancer
Hauptverfasser: Razavi, Pedram, Dickler, Maura N., Shah, Payal D., Toy, Weiyi, Brown, David N., Won, Helen H., Li, Bob T., Shen, Ronglai, Vasan, Neil, Modi, Shanu, Jhaveri, Komal, Caravella, Betty Ann, Patil, Sujata, Selenica, Pier, Zamora, Stephen, Cowan, Aimee M., Comen, Elizabeth, Singh, Andy, Covey, Anne, Berger, Michael F., Hudis, Clifford A., Norton, Larry, Nagy, Rebecca J., Odegaard, Justin I., Lanman, Richard B., Solit, David B., Robson, Mark E., Lacouture, Mario E., Brogi, Edi, Reis-Filho, Jorge S., Moynahan, Mary Ellen, Scaltriti, Maurizio, Chandarlapaty, Sarat
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2020
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7450824/
https://ncbi.nlm.nih.gov/pubmed/32864625
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s43018-020-0047-1
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge